Susquehanna International Group’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCVX
JT
RCM
DTC
Susquehanna International Group's PCVX Position: Q2 2026 in Review
Susquehanna International Group reduced its Vaxcyte (PCVX) stake by 76% in Q2 2026, selling an estimated $1.95M and leaving 11,206 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #9290.
Susquehanna International Group first reported a position in PCVX in Q2 2021 and has held it in 21 quarters since. The position peaked at $12M in Q1 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.
- Susquehanna International Group held 11,206 shares of Vaxcyte worth $651K as of Q2 2026.
- Susquehanna International Group sold 35,867 Vaxcyte shares in Q2 2026, an estimated $1.95M.
- Vaxcyte made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #9290 holding.
- Susquehanna International Group first reported a position in Vaxcyte in Q2 2021 and has held it in 21 quarters since.
- Susquehanna International Group's Vaxcyte position peaked at $12M in Q1 2025.
- 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.